checkAd
    Startseite > Aktien > Ligand Pharmaceuticals > Nachrichten
    Ligand Pharmaceuticals Aktie
    73,90
     
    USD
    +2,18 %
    +1,58 USD
    Letzter Kurs 04.05.24 Nasdaq
    73,88
     
    USD
    500 STK
    Geldkurs 03.05.24
    74,00
     
    USD
    300 STK
    Briefkurs 03.05.24
    ISIN: US53220K5048 · WKN: A1C9RN · SYM: LGND · USA

    Neueste Nachrichten

    Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
    23.04.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference
    08.04.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI
    03.04.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference
    05.03.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    04.03.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
    27.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa
    22.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires
    16.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
    13.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    01.02.24 · Business Wire (engl.) · Ligand Pharmaceuticals
    Fokus Aktien mit extremen Handelsvolumen am Donnerstag, den 18.01.2024
    18.01.24 · wO Chartvergleich · Cerus Corporation
    U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum
    05.01.24 · Business Wire (engl.) · Ligand Pharmaceuticals